Dr. Cull is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
65 International Dr
Greenville, SC 29615Phone+1 864-987-7000Fax+1 864-672-7852
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2009 - 2012
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2009
Certifications & Licensure
SC State Medical License 2015 - 2025
IL State Medical License 2009 - 2017
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.Patrick Smith, Benjamin Snyder, Maria McDaniel, Madeleine St Ville, Elizabeth Cull
Journal of Adolescent and Young Adult Oncology. 2024-12-01 - 1 citationsASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons
Targeted Oncology. 2024-05-01 - 9 citationsPhase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.Ahmad S Halwani, Carlos Panizo, Iris Isufi, Alex F Herrera, Craig Y Okada
Leukemia & Lymphoma. 2022-04-01
Abstracts/Posters
- Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)Elizabeth H. Cull, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...Elizabeth H. Cull, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
